Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?
The secondary stroke prevention trial showed that high/moderate-intensity statin therapy combined with ezetimibe and titrated to achieve LDLc <70 were equally effective (compared to goal LDLc <100). Overall, the most important determinant of risk reduction is the achieved LDLc, and so moderate inten...
From a stroke perspective, there is some evidence that adding ezetimibe to statin therapy helps achieve lower LDL-C levels. Some smaller studies have also shown decreased carotid intima-media thickness (IMT) and some reduction in cerebrovascular and cardiovascular events; however, the evidence is mi...
There is some evidence that moderate-intensity statin plus ezetimibe is as effective as high-intensity statin therapy in terms of lowering LDL cholesterol and reducing CV events although perhaps not as strong evidence as for high-intensity statin versus placebo or moderate-intensity statin. At the e...